Abstract
TAK‐931, a novel, selective, small‐molecule inhibitor of cell division cycle 7 has been investigated in multiple clinical trials in patients with advanced solid tumors. An integrated analysis using data from 2 clinical studies assessed effects of TAK‐931 on electrocardiogram QT intervals and heart rate (HR). Pharmacokinetic samples and matched triplicate electrocardiogram data were collected in 48 patients with cancer receiving oral administration of TAK‐931 50 or 80 mg once daily. The relationships between TAK‐931 plasma concentrations and the HR‐corrected QT interval via Fridericia (QTcF) or population (QTcP) and HR were analyzed using linear mixed‐effects models with fixed effects for day and time. At the geometric mean maximum TAK‐931 plasma concentrations after administration of 50 mg, an HR change of 3.40 beats per minute (90%CI, 1.86‐4.80) was predicted. Change in QTcF of −3.41 milliseconds (90%CI, −5.77 to −1.17) and QTcP of −2.02 milliseconds (90%CI, −4.15 to 0.0679) were estimated, indicating there was no effect of TAK‐931 on the QT intervals at a recommended phase 2 dose of 50 mg once daily for 14 days in a 21‐day cycle.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.